JP2003522112A - 不安障害の処置および予防への光学的に純粋な（ｒ）−トフィソパムの使用およびその組成物 - Google Patents

不安障害の処置および予防への光学的に純粋な（ｒ）−トフィソパムの使用およびその組成物

Info

Publication number
JP2003522112A
JP2003522112A JP2000578009A JP2000578009A JP2003522112A JP 2003522112 A JP2003522112 A JP 2003522112A JP 2000578009 A JP2000578009 A JP 2000578009A JP 2000578009 A JP2000578009 A JP 2000578009A JP 2003522112 A JP2003522112 A JP 2003522112A
Authority
JP
Japan
Prior art keywords
tofisopam
anxiety
disorder
anxiety disorder
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000578009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003522112A5 (enExample
Inventor
ドナルド・ダブリュー・ランドリー
ドナルド・エフ・クライン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vela Pharmaceuticals Inc
Original Assignee
Vela Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vela Pharmaceuticals Inc filed Critical Vela Pharmaceuticals Inc
Publication of JP2003522112A publication Critical patent/JP2003522112A/ja
Publication of JP2003522112A5 publication Critical patent/JP2003522112A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2000578009A 1998-10-27 1999-10-27 不安障害の処置および予防への光学的に純粋な（ｒ）−トフィソパムの使用およびその組成物 Pending JP2003522112A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10580398P 1998-10-27 1998-10-27
US60/105,803 1998-10-27
PCT/US1999/025040 WO2000024400A1 (en) 1998-10-27 1999-10-27 Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders and composition thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007136619A Division JP2007211028A (ja) 1998-10-27 2007-05-23 不安障害の処置および予防への光学的に純粋な（ｒ）−トフィソパムの使用およびその組成物

Publications (2)

Publication Number Publication Date
JP2003522112A true JP2003522112A (ja) 2003-07-22
JP2003522112A5 JP2003522112A5 (enExample) 2007-02-01

Family

ID=22307874

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000578009A Pending JP2003522112A (ja) 1998-10-27 1999-10-27 不安障害の処置および予防への光学的に純粋な（ｒ）−トフィソパムの使用およびその組成物
JP2007136619A Withdrawn JP2007211028A (ja) 1998-10-27 2007-05-23 不安障害の処置および予防への光学的に純粋な（ｒ）−トフィソパムの使用およびその組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007136619A Withdrawn JP2007211028A (ja) 1998-10-27 2007-05-23 不安障害の処置および予防への光学的に純粋な（ｒ）−トフィソパムの使用およびその組成物

Country Status (16)

Country Link
EP (1) EP1124556B1 (enExample)
JP (2) JP2003522112A (enExample)
AT (1) ATE269705T1 (enExample)
AU (1) AU1451900A (enExample)
BR (1) BR9914899A (enExample)
CA (1) CA2348281A1 (enExample)
DE (1) DE69918322T2 (enExample)
DK (1) DK1124556T3 (enExample)
ES (1) ES2224751T3 (enExample)
GB (1) GB2367748A (enExample)
HK (2) HK1040908B (enExample)
IL (2) IL142803A0 (enExample)
NZ (1) NZ511744A (enExample)
PT (1) PT1124556E (enExample)
WO (1) WO2000024400A1 (enExample)
ZA (1) ZA200103376B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513171A (ja) * 2003-12-03 2007-05-24 ヴェラ ファーマスーティカルズ インコーポレイテッド ２，３−ベンゾジアゼピン低投与量による上皮の炎症性疾患の治療

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649607B2 (en) 2001-05-18 2003-11-18 Vela Pharmaceuticals, Inc. Compositions and methods for treating or preventing convulsions or seizures
CA2483093A1 (en) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Use of milnacipran or a pharmaceutically acceptable salt thereof for treating chronic low back pain
US6864251B2 (en) 2002-12-03 2005-03-08 Vela Pharmaceuticals, Inc. Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines
JP2006514084A (ja) * 2002-12-03 2006-04-27 ヴェラ ファーマスーティカルズ インコーポレイテッド １−（３−ヒドロキシ−４−メトキシフェニル）−４−メチル−５−エチル−７，８−ジメトキシ−５ｈ−２，３−ベンゾジアゼピンの製薬組成物及びその用途
US7022700B2 (en) 2002-12-03 2006-04-04 Vela Pharmaceuticals, Inc. Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines
AU2003293405A1 (en) 2002-12-03 2004-06-23 Vela Pharmaceuticals, Inc. Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof
US6638928B1 (en) * 2002-12-03 2003-10-28 Vela Pharmaceuticals, Inc. Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines
CA2525273C (en) * 2003-05-16 2012-04-17 Vela Pharmaceuticals, Inc. Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (r) 2,3-benzodiazepine
FR2870539B1 (fr) * 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
US7541355B2 (en) 2005-05-23 2009-06-02 Vela Acquisition Corporation Conversion process for 2,3-benzodiazepine enantiomers
CN102836162A (zh) * 2012-04-10 2012-12-26 珠海亿邦制药股份有限公司 一种以托非索泮为活性成分的口服固体制剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK118660B (da) * 1966-12-09 1970-09-21 Egyt Gyogyszervegyeszeti Gyar Analogifremgangsmåde til fremstilling af 1-(3',4'-dimethoxyphenyl)-3-methyl-4-ethyl-6,7-dimethoxy-isoquinolin-N-imid.
ZA712798B (en) * 1970-11-06 1972-02-23 Egyt Gyogyszervegyeszeti Gyar New,pharmaceutically active 2,3-diazabicyclo(5.4.0)undecapentaene derivative and process for preparing same
HU178516B (en) * 1978-05-05 1982-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing enanthiomeres of 1-bracket-3,4-dimethoxy-phenyl-bracket closed-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine and pharmacologically acceptable soles of the /-/-enanthiomere
HU209530B (en) * 1988-08-31 1994-07-28 Magnezitipari Muevek Rt Process for manufacturing of cromit-like, fire resistant materials

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513171A (ja) * 2003-12-03 2007-05-24 ヴェラ ファーマスーティカルズ インコーポレイテッド ２，３−ベンゾジアゼピン低投与量による上皮の炎症性疾患の治療

Also Published As

Publication number Publication date
EP1124556A1 (en) 2001-08-22
JP2007211028A (ja) 2007-08-23
WO2000024400A1 (en) 2000-05-04
IL142803A (en) 2006-10-05
IL142803A0 (en) 2002-03-10
CA2348281A1 (en) 2000-05-04
ZA200103376B (en) 2003-09-09
GB2367748A8 (en) 2002-12-19
DE69918322T2 (de) 2005-09-15
BR9914899A (pt) 2001-07-17
HK1040908A1 (en) 2002-06-28
AU1451900A (en) 2000-05-15
ES2224751T3 (es) 2005-03-01
HK1040908B (en) 2005-04-22
GB2367748A (en) 2002-04-17
NZ511744A (en) 2004-04-30
DK1124556T3 (da) 2004-10-11
HK1046500A1 (zh) 2003-01-17
DE69918322D1 (de) 2004-07-29
PT1124556E (pt) 2004-10-29
EP1124556B1 (en) 2004-06-23
ATE269705T1 (de) 2004-07-15
GB0111739D0 (en) 2001-07-04

Similar Documents

Publication Publication Date Title
US6080736A (en) Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam
JP2007211028A (ja) 不安障害の処置および予防への光学的に純粋な（ｒ）−トフィソパムの使用およびその組成物
CA2832157C (en) Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder
Cohen et al. Evidence for the involvement of dopamine receptors in ethanol-induced hyperactivity in mice
JP5656883B2 (ja) エスゾピクロンを用いる治療方法
CZ20004280A3 (cs) Lék pro léčbu bipolárních poruch a farmaceutický prostředek
CA3182412A1 (en) Advantageous benzothiophene compositions for mental disorders or enhancement
CN102105059A (zh) 用于睡眠障碍和其他疾病的方法和组合物
CZ20004279A3 (cs) Lék pro léčení nepoddajné deprese a farmaceutická kompozice
JP7261942B2 (ja) 有機化合物
CA2478227A1 (en) Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
IL149134A (en) Pharmaceutical compositions containing tofisopam
Ciraulo et al. Sedative hypnotics
BRPI0713733A2 (pt) métodos para diminuir os sintomas de depressão e para tratar uma ou mais condições psicológicas, composição farmacêutica e kit
MXPA01004109A (en) Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders and composition thereof
AU2005201012A1 (en) Use of Optically Pure (R)-Tofisopam for Treating and Preventing Anxiety Disorders and Composition Thereof
US20060148841A1 (en) Pharmaceutical composition comprising combination of non-alkaloid and alkaloid-based component for treating skeletal muscle spasm
HK40071167A (en) Methods for treating behavioral and psychological symptoms in patients with dementia
Sacklecha Drug and Excipient Compatibility Study of Selected B Blockers
MXPA00011353A (es) Uso de olanzapida en combinación con fluoxetina para terapia de la depresión refractaria
WO2005049039A1 (en) Combinations comprising ampa receptors antagonists for the treatment of affective and attention deficit disorders
MXPA00011354A (en) Combination therapy for treatment of bipolar disorders
MXPA02005071A (es) Composiciones y metodos para el tratamiento o prevencion de convulsiones o ataques

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20060530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060905

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060912

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20061206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20061206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070123